RHYTHM PHARMACEUTICALS, INC. Cash and Cash Equivalents, Period Increase (Decrease)
RHYTHM PHARMACEUTICALS, INC. (RYTM) reported Cash and Cash Equivalents, Period Increase (Decrease) of $27.70 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-12.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-03-12
- RHYTHM PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was $6.32M.
- RHYTHM PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2016-12-31 was -$6.08M.
- RHYTHM PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $27.70M.
- RHYTHM PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$28.33M, a 181.60% decline from fiscal 2015.
- RHYTHM PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2015 was $34.72M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|
| 2017-12-31 | $6.32M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $27.70M 10-K · filed 2018-03-12 | |
| 2017-09-30 | $21.37M 10-Q · filed 2017-11-14 | ||
| 2016-12-31 | -$6.08M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | -$28.33M 10-K · filed 2018-03-12 | |
| 2016-09-30 | -$22.25M 10-Q · filed 2017-11-14 | ||
| 2015-12-31 | $34.72M 10-K · filed 2018-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |